Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy - CHOLINET (CHOLesterol Italian Inclisiran NETwork)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

Evaluation of adherence, persistence and efficacy of treatment with Inclisiran in a real-life Italian population

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients under Inclisiran treatment

Locations
Other Locations
Italy
Federico II University of Naples, Department of Advanced Biomedical Sciences
RECRUITING
Napoli
Time Frame
Start Date: 2022-11-01
Estimated Completion Date: 2024-11-01
Participants
Target number of participants: 1000
Treatments
Subjects with hyperlipidaemia under Inclisiran treatment
Related Therapeutic Areas
High Cholesterol
Sponsors
Leads: Federico II University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

German Inclisiran Network: Retrospective Registry of Patients Being Treated With the siRNA Inclisiran in Germany

German Inclisiran Network: Retrospective Registry of Patients Being Treated With the siRNA Inclisiran in Germany

Enrollment Status: Recruiting
Publish Date: July 07, 2022

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol

Enrollment Status: Recruiting
Publish Date: July 30, 2025
Intervention Type: Drug
Study Phase: Phase 3

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol

Enrollment Status: Recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Phase: Phase 3
View All